Biovotion: final closing of CHF13M Series A financing round

Biovotion, a leading wearable physiology monitoring company, announces the final closing of its Series A round. Investors include Swiss Re and the corporate Venture Capital arm of a major global consumer organisation.

Biovotion is a digital health company providing integrated solutions with connected hardware, value-added data analytics and monitoring services. The company has announced the final closing of its oversubscribed CHF13M Series A financing round. Following earlier closings with Swiss Re as the lead investor and Harmony Medical Inc., a Hong-Kong based investment company. The Series A round has now been closed with the addition of the corporate Venture Capital arm of a major global consumer organisation, and a UK based institutional investor with dedicated experiences in the IoT space. Existing investor STMicroelectronics NV (EPA: STM) continued their support and also participated in the round.

The addition of a fourth corporate VC to the shareholder group solidifies Biovotion’s ambition to partner with those committed to driving digital transformation efforts in the medical and health industries. Biovotion continues to promote the decentralisation of healthcare provision, with a focus on empowering end users and patients in a highly scalable and bidirectional manner.

Biovotion is currently unfolding its Machine Learning-supported digital health platform. This consists of the Everion, a unique medical-grade physiological monitoring wearable, in combination with a powerful data analytics engine. Everion is CE medical class 2a approved as well as FDA 510(k) exempt listed as a medical device.

(Press release)